Brege Laura reported change-of-control tender involving 23,715 shares of Pacira BioSciences, Inc. at $36.50 for −$866k on Nov 17, 2026

Change-of-control tender
Form 4 code U. Disposition pursuant to a tender of shares in a change-of-control transaction.
Director
DIR
Filed Nov 17, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$865,597.50Shares × reported price
Shares traded
23,715Common Stock
Price per share
$36.50Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
6,405Direct
Trade date
Nov 17, 2026Change-of-control tender
Filed
Nov 17, 2026, 4:35 PM ET0-day reporting delay
Accession
0001628280-26-074525Code U · Transaction 403618
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Related trades are temporarily unavailable. Open the SEC filing for the complete report, or reload this page.

PCRX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
PCRX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 24, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −0.4%1w ago +0.1%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of October 8, 2026, by and among Pacira BioSciences, Inc. ("Issuer"), Viatris Inc. ("Viatris") and Peach Purchaser Sub Inc. ("Purchaser") (the "Merger Agreement"), pursuant to which Purchaser consummated a cash tender offer (the "Offer") to purchase all of the outstanding shares of Issuer's common stock (the "Shares") for $36.50 per Share, net of applicable withholding taxes and without interest (the "Offer Price"), after which Purchaser merged with and into Issuer with Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). On November 17, 2026, the effective time of the Merger (the "Effective Time"), each Share was converted into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award ("RSU") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares issuable in settlement of such RSU, multiplied by (ii) the Offer Price, subject to applicable tax withholdings F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares ("Option") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per Share under such Option, subject to applicable tax withholdings. Each Option that was outstanding immediately prior to the Effective Time which had a per Share exercise price greater than or equal to the Offer Price was cancelled at the Effective Time with no consideration payable.